Aethlon Medical, Inc. to Webcast, Live, at Retail on February 7th

 Aethlon Medical, Inc. to Webcast, Live, at Retail on
                                 February 7th

Company invites Main Street and Wall Street investors to attend interactive
real-time virtual conference

PR Newswire

NEW YORK, Feb. 6, 2013

NEW YORK, Feb. 6, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTC: AEMD),
announced today that Chairman and Chief Executive officer, James Joyce will
present at

DATE:     February 7, 2013
TIME:    2:00PM EST
LINK:> red "register/ watch event now"

This will be a live, interactive online event where investors are invited to
ask the company questions in real-time- both in the presentation hall as well
as the company's "virtual trade booth." If attendees are not able to join the
event live on the day of the conference, an on-demand archive will be
available for 90 days.

It is recommended that investors pre-register to save time and receive event

About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical
needs in cancer, infectious disease, and other life-threatening conditions.
Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides
the basis for a new class of devices the rapid, yet selective removal of
disease promoting particles from the entire circulatory system. At present,
The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to
address infectious disease and cancer, and a medical device being developed
under a 5-year contract with Defense Advanced Research Projects Agency (DARPA)
to reduce the incidence of sepsis in combat-injured soldiers. For more
information, please visit

About The Aethlon Hemopurifier®
The Aethlon Hemopurifier® is a first-in-class medical device that selectively
targets the rapid clearance of infectious viral pathogens and
immunosuppressive proteins from the entire circulatory system. In the
treatment of Hepatitis C virus (HCV), human studies have demonstrated that
Hemopurifier® therapy may improve immediate, rapid and sustained virologic
response rates when administered in the first few days of standard-of-care
drug therapy. In addition to accelerating viral load depletion, post-treatment
analysis of the Hemopurifier® has documented the capture of up to 300 billion
HCV copies of HCV during a single six-hour treatment. Access to Hemopurifier®
therapy is available on a compassionate-use basis through the Medanta Medicity
Institute (Medicity), a leading center for medical tourism in India. The
Medicity is offering treatment access to infected individuals who previously
failed or subsequently relapsed standard-of-care drug regimens. The
Hemopurifier® is also being offered as a salvage therapy to infected
individuals who suffer a viral breakthrough during standard-of-care therapy.
U.S. studies of the Hemopurifier® are currently pending approval of an IDE
submitted to FDA.

The Aethlon Hemopurifier® and Cancer
In addition to the opportunity to address a broad-spectrum of infectious viral
pathogens, the Hemopurifier® has been discovered to capture tumor-derived
exosomes underlying several forms of cancer. Tumor-derived exosomes have
recently emerged to be a vital therapeutic target in cancer care. These
microvesicular particles suppress the immune response in cancer patients
through apoptosis of immune cells and their quantity in circulation correlates
directly with disease progression. Beyond possessing immunosuppressive
properties, tumor-derived exosomes facilitate tumor growth, metastasis, and
the development of drug resistance. By addressing this unmet medical need,
the Hemopurifier® is positioned as an adjunct to improve established cancer
treatment regimens.

Since 2010,, created by BetterInvesting (NAIC)
PR NewswireandMUNCmedia, has been the only monthly virtual investor
conference series that provides an interactive forum for presenting companies
to meet directly with retail investors using a graphically-enhanced online

Designed to replicate the look and feel of location-based investor
conferences, Retail Investor Conferences unites PR Newswire's leading-edge
online conferencing and investor communications capabilities with
BetterInvesting's extensive retail investor audience network and MUNCmedia's
sophisticated retail investor targeting.

SOURCE Aethlon Medical, Inc.

Contact: Aethlon Medical, Inc., James A. Joyce, Chairman and CEO,
+1-858-459-7800 x301,; Jim Frakes, Chief Financial
Officer, +1-858-459-7800 x300,; or Marc Robins,
+1-877-276-2467,; or,
Bradley H. Smith,, +1-201-942-7157
Press spacebar to pause and continue. Press esc to stop.